



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

Dias, André H.; Jochumsen, Mads R.; Zacho, Helle D.; Munk, Ole L.; Gormsen, Lars C.

Published in:
EJNMMI Research

DOI (link to publication from Publisher):
[10.1186/s13550-023-00981-8](https://doi.org/10.1186/s13550-023-00981-8)

Creative Commons License
CC BY 4.0

Publication date:
2023

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Dias, A. H., Jochumsen, M. R., Zacho, H. D., Munk, O. L., & Gormsen, L. C. (2023). Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007. *EJNMMI Research*, 13(1), 31. [31]. <https://doi.org/10.1186/s13550-023-00981-8>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

ORIGINAL RESEARCH

Open Access



Multiparametric dynamic whole-body PSMA PET/CT using [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007

André H. Dias^{1*} , Mads R. Jochumsen^{1,3} , Helle D. Zacho^{2,4} , Ole L. Munk^{1,3†} and Lars C. Gormsen^{1,3†}

Abstract

Background Routine prostate-specific membrane antigen (PSMA) positron emission tomography (PET) performed for primary staging or restaging of prostate cancer patients is usually done as a single static image acquisition 60 min after tracer administration. In this study, we employ dynamic whole-body (D-WB) PET imaging to compare the pharmacokinetics of [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007 in various tissues and lesions, and to assess whether Patlak parametric images are quantitative and improve lesion detection and image readability.

Methods Twenty male patients with prostate cancer were examined using a D-WB PSMA PET protocol. Ten patients were scanned with [⁶⁸Ga]Ga-PSMA-11 and ten with [¹⁸F]PSMA-1007. Kinetic analyses were made using time-activity curves (TACs) extracted from organs (liver, spleen, bone, and muscle) and lesions. For each patient, three images were produced: SUV + Patlak parametric images (K_i and DV). All images were reviewed visually to compare lesion detection, image readability was quantified using target-to-background ratios (TBR), and K_i and DV values were compared.

Results The two PSMA tracers exhibited markedly different pharmacokinetics in organs: *reversible* for [⁶⁸Ga]Ga-PSMA-11 and *irreversible* for [¹⁸F]PSMA-1007. For both tracers, lesions kinetics were best described by an irreversible model. All parametric images were of good visual quality using both radiotracers. In general, K_i images were characterized by reduced vascular signal and increased lesion TBR compared with SUV images. No additional malignant lesions were identified on the parametric images.

Conclusion D-WB PET/CT is feasible for both PSMA tracers allowing for direct reconstruction of parametric K_i images. The use of multiparametric PSMA images increased TBR but did not lead to the detection of more lesions. For quantitative whole-body K_i imaging, [¹⁸F]PSMA-1007 should be preferred over [⁶⁸Ga]Ga-PSMA-11 due to its irreversible kinetics in organs and lesions.

Keywords Dynamic whole-body PET, PSMA, Parametric imaging, Patlak, Oncology, Prostate cancer

[†]Ole L. Munk and Lars C. Gormsen contributed equally to this work.

*Correspondence:

André H. Dias
andre.dias@auh.rm.dk

Full list of author information is available at the end of the article

Introduction

Prostate cancer (PCa) is one of the most frequently occurring cancers in the male population [1] and is now the second most common cause of death from malignancy in this group [2]. Positron emission tomography (PET) is an integral part of PCa management, with prostate-specific membrane antigen (PSMA)-targeted tracers used for primary staging and also in the evaluation of biochemical relapse, assisting in therapy planning and disease management [3, 4].

PSMA is a cellular transmembrane surface protein that is overexpressed in PCa. Unfortunately, PSMA is not prostate-specific [5] and also binds to cells in other tissues as well as to the neovasculature in other malignancies [6]. Several PSMA radiotracers have been produced [7]. Labelled predominantly with ^{68}Ga (^{68}Ga) and ^{18}F (^{18}F), these radiotracers have been made commercially available and disseminated in clinical trials and daily clinical practice. The use of ^{68}Ga radiolabelled compounds is widely implemented. However, production of ^{68}Ga -radiotracers requires an on-site ^{68}Ga generator, and ^{68}Ga radiotracers have a relatively shorter half-life and longer positron range than ^{18}F labelled tracers, resulting in images with lower spatial resolution.

Conventional static PSMA PET imaging is usually performed 60 min after tracer administration, although modified protocols with scanning at different time points have been suggested to improve image quality [8, 9]. However, most previous studies have been limited by the single timepoint evaluation of conventional PET, and only few comprehensive studies of PSMA pharmacokinetics have been attempted. These have mostly applied a dynamic protocol on conventional field of view cameras constrained to two bed positions over the pelvis [10–15], with only one truly “whole-body” dynamic acquisition study performed on a total-body PET/CT scanner [16]. Using dynamic PET with [^{68}Ga]Ga-PSMA-11 has shown to increase identification rates of both primary PCa and local recurrence [12, 17], suggesting that dynamic whole-body (D-WB) PSMA PET imaging could outperform static PSMA PET.

For the analysis of PSMA kinetics, a two-tissue compartment model can be applied to describe the tracer exchanges between plasma and tissue. In this case, the first compartment (unbound compartment) represents the free unbound tracer in interstitial fluid, while the second compartment (bound compartment) represents tracer bound to the PSMA receptors, with the transport rate k_3 correlating with tracer binding and internalization, and k_4 with the dissociation of the tracer from the receptor and externalization. For PCa lesions, the $k_4 \approx 0$, as the binding is predominantly irreversible [11].

Previously, dynamic PET acquisition was limited to a single field of view and technically difficult to perform due to the necessity of acquiring arterial blood samples to accurately determine the input function. Given the disseminated nature of malignancies such as PCa and the volume of patients referred for pre-therapy PET, dynamic PET has not been implemented in routine oncological work-up. However, this may be about to change.

Recently introduced methodology [18, 19] allows for D-WB PET acquisitions in conventional PET scanners, by applying the linear Patlak model [20, 21] to a multi-pass continuous WB dynamic PET acquisition. This imaging protocol provides not only the conventional standardized uptake value (SUV) images, but also multiparametric images based on Patlak kinetic modelling [22]. These images are the K_i images (representing the effective tracer binding by the PSMA receptors) and DV images (representing the distribution volume of non-trapped tracer in the reversible compartments and the fractional blood volume). These advances have prompted renewed interest and research in the use of dynamic PET for oncological imaging as reviewed elsewhere [23, 24]. While the multiparametric D-WB protocol has been successfully applied for 2- ^{18}F fluoro-2-deoxy-D-glucose (^{18}F)FDG [25–27], it has until now only to a lesser degree been explored for other tracers.

At our department, we recently transitioned from a ^{68}Ga labelled tracer (^{68}Ga]Ga-PSMA-11) to an ^{18}F labelled tracer (^{18}F]PSMA-1007) for routine clinical PSMA PET allowing for a comparison of the two radiotracers. With this study, we therefore aimed to evaluate the tissue pharmacokinetics of these two tracers, the image quality and clinical impact of multiparametric D-WB PSMA PET imaging, and the quantitative accuracy of the resulting parametric values.

Materials and methods

Patient population

This study was a retrospective analysis of data. Participants were recruited from all patients referred for PSMA PET/CT as part of their clinical evaluation if they were deemed fit to lie still for 70 min during scanning. The study was approved by the local ethics committee in the Central Denmark Region (1-10-72-188-19).

D-WB PSMA data were obtained from 20 male patients with known prostate cancer. Ten patients were scanned with [^{68}Ga]Ga-PSMA-11 and ten patients with [^{18}F]PSMA-1007.

Data acquisition and image reconstruction

The study participants were scanned on a Siemens Biograph Vision 600 PET/CT scanner (Siemens Healthineers, Knoxville, USA) with a 26.2-cm axial field of

view. A fully automated multiparametric PET/CT acquisition protocol (Multiparametric PET Suite AI, Siemens Healthineers, Knoxville, USA) was used.

[⁶⁸Ga]Ga-PSMA-11 cohort (N=10): These subjects were scanned with a 76-min multiparametric PET acquisition protocol, started at the time of an injection of [⁶⁸Ga]Ga-PSMA-11 (2 MBq/kg). The PET protocol consisted of 1) a 6-min dynamic scan with the bed fixed at the chest region, and 2) a 70-min dynamic WB PET scan consisting of seven continuous 10-min WB passes.

[¹⁸F]PSMA-1007 cohort (N=10): A 70-min multiparametric PET acquisition protocol was started at the time of an injection of [¹⁸F]PSMA-1007 (2 MBq/kg). The PET protocol consisted of 1) a 6-min dynamic scan with the bed fixed at the chest region, and 2) a 64-min dynamic WB PET scan consisting of 16 continuous bed motion passes: 7 × 2-min WB passes followed by 9 × 5-min WB passes.

The dynamic image acquisition protocols were therefore not entirely identical. In practice, this meant that 40–70 min direct parametric reconstructions for [⁶⁸Ga]Ga-PSMA-11 were performed on 3 10-min images, while for [¹⁸F]PSMA-1007 they were calculated from 6 5-min images. However, since all multiparametric images were based on 30-min D-WB PET data, we expect this variation of the frame length to have a minimal impact on image quality and noise of the multiparametric images (*Ki* and *DV*) [18].

For both tracers, multiparametric images (*Ki* and *DV*) were reconstructed using the data from 40-to-70-min post-injection and the image-derived input function (IDIF). This reconstruction protocol was performed using the direct Patlak reconstruction in the Multiparametric PET Suite AI software from Siemens Healthineers. A standard-of-care static SUV image was reconstructed using data from 60-to-70-min post injection. The PET reconstruction parameters for D-WB: For the 10-min SUV image, we used TrueX + time-of-flight, four iterations, five subsets, 440 × 440 matrix, 2-mm Gaussian filter, and relative scatter correction (reconstruction time 2.5 min). Parametric images of *Ki* and *DV* were generated using the direct Patlak reconstruction method with non-negativity constraints using list-mode data from multiple passes (40–70 min), TrueX + time-of-flight, eight iterations, five subsets, 30 nested loops, 440 × 440 matrix, 2-mm Gaussian filter, and relative scatter correction (reconstruction time 13.5 min). For image-based kinetic analyses, we also made a 0–6-min dynamic series of the chest region (12 × 5 s, 6 × 10 s, 8 × 30 s; reconstruction time 5 min), and a 6–70-min dynamic WB series (16 passes, reconstruction time 23 min), using the same reconstruction parameters as the static SUV image. This results in

complete 0–70-min dynamic PET data coverage of the chest region.

After image acquisition, the automated multiparametric scan protocol automatically identified the aorta on the low-dose WB CT scan a technology from Siemens Healthineers known as automated learning and parsing of human anatomy (ALPHA) [28] and placed a cylindrical volume of interest (VOI) (1.6 mm³) on the descending aorta to extract the IDIF from the full dynamic PET series of the chest region. Such an IDIF is robust and can be used to replace an arterial blood input function for precise quantitative Patlak modelling [29].

Image analysis and VOI delineation

Multiparametric images were visually evaluated by two nuclear medicine physicians using Hermes Gold Client v.2.5.0 (Hermes Medical Solutions AB, Stockholm, Sweden). VOI delineation of the multiparametric images was performed using PMOD[®] 4.0 (PMOD Technologies Ltd, Zürich, Switzerland). Semiquantitative values of *SUV*_{max} and *SUV*_{mean} were obtained from the conventional PET reconstructions, whereas *Ki* and *DV* values were extracted from the multiparametric images.

For each patient, VOIs were analysed from areas of tissue without evidence of pathology. Specifically, we performed delineation of an area of the liver, spleen, parotid gland, lacrimal gland, healthy bone, muscle, benign ganglia (with active PSMA signal) in the pelvis and thorax, and bladder. Areas with pathologically increased uptake of PSMA were identified and delineated using an isocontouring method of 55% of *SUV*_{max} in the VOI [30]. Thus, we outlined the primary tumour in the prostate, as well as lymph node and bone lesions. In patients with an uncountable number of active lesions, for example in disseminated skeletal disease, up to ten individual foci were chosen for delineation. Background regions were delineated in the vicinity of these target lesions, corresponding to an elongated ROI drawn in adjoining tissue in at least three consecutive slices. The individual methodology used to delineate these areas can be found in Additional file 1: Table S1, and an example of a lesion and background delineation can be found in Additional file 1: Fig. S1.

We used target-to-background ratio (TBR) as an objective metric for quantitative assessment of 'lesion detectability'. Detectable lesions require a TBR > 1, and a higher TBR indicates better lesion detectability.

Comparison of multiparametric and image-based *Ki* and *DV* values

The estimates of kinetic parameters obtained through indirect image-based analysis can differ from those obtained by direct reconstruction of parametric images,

with the latter exhibiting more favourable bias and noise characteristics, as demonstrated in reference [31]. The noise and bias in Ki images are influenced by factors such as the specific implementation of the optimization algorithm, the mathematical formulation of the Patlak model, and the utilization of non-negativity constraints [32, 33]. We therefore compared the kinetic parametric estimates using the two methods. The image-based parameters were calculated by linear Patlak analysis in PMOD[®] 4.0, using the general kinetic modelling tool (PKIN) with the lumped constant set to 1 and discarding fits with negative values. The direct reconstructed values were obtained using the Multiparametric PET Suite AI from Siemens Healthineers.

Kinetic analysis

70-min dynamic scan data from the fixed bed at the chest region was analysed using a two-tissue compartment model (2CM) and the 70-min IDIF using PMOD's PKIN module. More specifically we analysed VOIs in the liver, spleen, healthy bone (thoracic vertebra), muscle (paravertebral) and any of the previously delineated PSMA avid lesions that were included in this limited scan field-of-view. Parameter estimates for a reversible ($k_4 > 0$) and irreversible ($k_4 = 0$) 2CM were obtained and compared with the parameters from the irreversible Patlak model [20] and the reversible Logan Model [34]. Akaike information criterion (AIC) [35] was used to select the CM that best fitted each tissue and for each tracer.

Statistical analysis

Statistical analyses were performed using GraphPad Prism 9.2.0. Statistical tests were used for group comparisons (paired/unpaired) and to assess whether data were normally distributed. Welch's T test was performed for normal distributed data (liver, spleen, bone, and benign ganglia), while the Mann–Whitney test was performed for non-normal distributed data (prostate lesions, lymph node lesions, bone lesions, parotid gland, lacrimal gland, and muscle).

Pearson's correlation analysis was performed for the relation between Ki and SUV values. P values of < 0.05 were considered significant. Continuous group data are presented as mean \pm SD or median (range) as appropriate. Time-series are presented as mean \pm SEM.

Results

Time-activity curves

The whole-body dynamic series contained TACs of the analysed organs as well of the pathological findings as presented in Fig. 1. Lesions displayed continuously increasing PSMA activity over time, independent of the tracer used. However, there was a difference in tracer

behaviour when analysing the healthy organ areas. While gradual increase (for parotid or lacrimal glands) or decrease (for bone and muscle) was observed for both tracers, the kinetics of hepato-splenic activity appeared to differ between tracers. Where $[^{68}\text{Ga}]\text{Ga-PSMA-11}$ showed decreasing activity in the liver and spleen, a gradually increasing PSMA activity over time was seen with $[^{18}\text{F}]\text{PSMA-1007}$.

Full kinetic analysis using 2CM

The two PSMA tracers exhibited significantly different pharmacokinetics in normal organs (liver, spleen, bone, and muscle) as measured by AIC values. For $[^{68}\text{Ga}]\text{Ga-PSMA-11}$, the normal organ TACs were best fitted using the reversible 2CM. For $[^{18}\text{F}]\text{PSMA-1007}$, the normal organ TACs were best fitted using the irreversible 2CM except for muscle that were best fitted using a reversible model. For both tracers, the lesions were best fitted using the irreversible 2CM. The AIC values are shown in Additional file 1: Fig. S2.

The multiparametric images are based on the Patlak model that assumes irreversible kinetics. For normal organs, Fig. 2 shows the correlation between values from the parametric Ki images as function of the Ki values from full kinetic analyses using the reversible and irreversible 2CM, respectively. For $[^{18}\text{F}]\text{PSMA-1007}$, there was excellent correlations, whereas for $[^{68}\text{Ga}]\text{Ga-PSMA-11}$, the correlation was poor, and the multiparametric Ki values were strongly biased. However, for $[^{68}\text{Ga}]\text{Ga-PSMA-11}$, we found good correlation between the total distribution volume calculated using Logan analysis and full kinetic modelling using the reversible 2CM (Additional file 1: Fig. S3A, B) as expected for organs with reversible kinetics. For lesions, the correlations between the Ki estimates were excellent for both tracers as seen in Fig. 2 and Additional file 1: Fig. S3C.

Comparison of multiparametric and image-based Ki values

For both $[^{68}\text{Ga}]\text{Ga-PSMA-11}$ and $[^{18}\text{F}]\text{PSMA-1007}$, we found excellent correlation ($r^2 = 0.99$, $p < 0.0001$) between Ki values extracted from the multiparametric images (direct reconstruction) versus image-based calculations performed in PMOD's PKIN module (Additional file 1: Fig. S4).

Visual analysis of images

The clinical indications and characteristics of the study subjects are shown in Table 1.

All D-WB PET images were of good visual quality as shown in the examples below (Fig. 3).

In general, PSMA Ki images were characterized by reduced signal in vascularized tissues (liver, mediastinum, spleen, and large vessels). The DV images were




Fig. 1 Representation of time activity curves for SUV_{mean} values. In blue are the TACs for [⁶⁸Ga]Ga-PSMA-11, in red the curves for [¹⁸F]PSMA-1007. On the left column, the plots for healthy organs: Above: liver and spleen; middle: parotid gland and lacrimal gland; below: bone and muscle. On the right column: Above: prostate lesions; middle: lymph node lesions; below: skeletal lesions

characterized by high signal intensity in the vascularized organs and also by the presence of signal from both benign and malignant lesions. The vascular [¹⁸F]PSMA-1007 signal displayed on DV images appears to be more intense than that of [⁶⁸Ga]Ga-PSMA-11.

The [⁶⁸Ga]Ga-PSMA-11 cohort consisted of nine primary staging and one relapse evaluations. Malignant disease was found in 9/10 scans. One primary staging patient had localized prostatic disease, while seven patients had disease dissemination to lymph nodes and/




Fig. 2 Correlation between values from the parametric Ki images as function of the Ki values from full kinetic analyses using the reversible 2CM (left) and irreversible 2CM (right). In blue are the data for [68Ga]Ga-PSMA-11, in red [18F]PSMA-1007. For the analysed organs (A and B), excellent correlation is seen for [18F]PSMA-1007, whereas for [68Ga]Ga-PSMA-11, the correlation was poor, and the multiparametric Ki values were strongly biased. For lymph node and bone lesions (C and D), excellent correlation is seen for both tracers

or bone. The relapse study patient showed disseminated lymph node disease. A total of 274 VOIs were delineated (including healthy organs, targets, benign ganglia, and background areas).

The [18F]PSMA-1007 cohort consisted of six primary staging evaluations, two disease progression studies, and two relapse evaluations. Malignant disease was found in 9/10 scans. In the staging and progression scans, one patient presented with localized prostatic disease, and the rest with disseminated disease. One patient with suspected disease relapse showed no signs of active disease, whereas the other had bone metastases. A total of 210 VOIs were delineated.

In all 20 patients, visual lesion detection in terms of the number of identified lesions was almost identical between SUV and parametric images, with a few notable exceptions. In two patients, SUV images revealed PSMA avid foci in soft tissue of the shoulder region, as shown in Additional file 1: Fig. S5. These foci were absent from the Ki images and visible on the DV images indicating (correctly) that the SUV image PSMA avidity was due to free tracer.

One patient was diagnosed with a hepatocellular carcinoma of the liver. As seen in Additional file 1: Fig. S6, although the Ki images reduced liver background

Table 1 Characteristics of the study population

Patient no	Age	Indication	Previous treatment or other notes	PSA ($\mu\text{g/L}$)	Gleason	Tracer	Dose (MBq)
1	70	Primary staging		6.4	7	[⁶⁸ Ga]Ga-PSMA-11	151
2	53	Primary staging		7.2	7	[⁶⁸ Ga]Ga-PSMA-11	151
3	68	Primary staging		30	7	[⁶⁸ Ga]Ga-PSMA-11	163
4	67	Relapse	Prostatectomy and LN extraction	4	8	[⁶⁸ Ga]Ga-PSMA-11	198
5	78	Primary staging		11	7	[⁶⁸ Ga]Ga-PSMA-11	182
6	63	Primary staging	Increased prostate size, negative previous biopsies	35	NA	[⁶⁸ Ga]Ga-PSMA-11	135
7	60	Primary staging		47	8	[⁶⁸ Ga]Ga-PSMA-11	177
8	71	Primary staging		95	9	[⁶⁸ Ga]Ga-PSMA-11	175
9	57	Primary staging		160	7	[⁶⁸ Ga]Ga-PSMA-11	204
10	69	Primary staging		14.6	7	[⁶⁸ Ga]Ga-PSMA-11	194
11	75	Progression	Medical castration	707.7	7	[¹⁸ F]PSMA-1007	151
12	73	Relapse	Prostatectomy	0.2	8	[¹⁸ F]PSMA-1007	201
13	66	Progression	Active surveillance	9.6	6	[¹⁸ F]PSMA-1007	181
14	63	Primary staging		32.5	8	[¹⁸ F]PSMA-1007	209
15	64	Relapse	Prostatectomy + RT	0.2	7	[¹⁸ F]PSMA-1007	197
16	71	Primary staging	Increased prostate size, negative previous biopsies	14	NA	[¹⁸ F]PSMA-1007	240
17	65	Primary staging		72.4	8	[¹⁸ F]PSMA-1007	236
18	78	Primary staging		31.6	7	[¹⁸ F]PSMA-1007	205
19	68	Primary staging		5.1	9	[¹⁸ F]PSMA-1007	205
20	71	Primary staging		5.9	7	[¹⁸ F]PSMA-1007	164

activity and thus improved TBR, the liver lesion was in fact more easily identified on SUV and DV images.

Quantitative analysis of lesion detectability

As expected, [¹⁸F]PSMA-1007 prostate and bladder TBR was better than [⁶⁸Ga]Ga-PSMA-11 (Additional file 1: Fig. S7). In addition, the observed lesion TBR was superior in the K_i images as indicated by the location of 135/145 lesions above the line of identity (Fig. 4). In ten lesions, $\text{TBR}_{\text{SUV}_{\text{mean}}} > \text{TBR}_{K_i_{\text{mean}}}$, all of which were [⁶⁸Ga]Ga-PSMA-11 PET/CT scans (eight lymph nodes, one bone lesion, one prostate lesion).

The SUV_{mean} in the liver, bone and muscle was significantly different ($p < 0.05$) between [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007. For the parametric images, K_i_{mean} values differed significantly between the two tracers in the liver, muscle, parotid and lacrimal glands. We saw no significant difference in the distribution of SUV_{mean} activity between tracers in the primary tumour of the prostate, in lymph nodes or in the physiologic uptake in ganglia. However, the skeletal lesions showed significantly lower activity with [¹⁸F]-PSMA-1007. K_i_{mean} values were significantly greater using [⁶⁸Ga]Ga-PSMA-11 than [¹⁸F]PSMA-1007 for nodal and bone lesions but not in the prostate or in benign ganglia (Fig. 5; data for benign ganglia is shown in Additional file 1: Fig. S8, data for SUV_{max} is shown in Additional file 1: Fig. S9).

An excellent correlation between quantitative (K_i_{mean}) and semi-quantitative (SUV_{mean}) measurements of lesion metabolism were seen for both tracers (Fig. 6), slightly higher for [¹⁸F]PSMA-1007 ([⁶⁸Ga]Ga-PSMA-11: $r^2 = 0.93$; [¹⁸F]PSMA-1007: $r^2 = 0.98$).

Discussion

PSMA multiparametric PET images for both radiotracers were of good visual quality as reflected by the excellent TBR and overall image appearance. In general, lesion TACs were roughly similar between the two radiotracers, whereas organ TACs differed noticeably due to the different modes of excretion. Finally, the parametric values derived from the image-based kinetic analyses compared well with the parametric images using direct reconstruction allowing for simple acquisition of whole body PSMA kinetics.

Multiparametric K_i imaging assumes an irreversible kinetic model in organs and lesions. Tissues with reversible uptake will have underestimated K_i depending on the degree of reversibility that may differ between tissues. We found that the multiparametric K_i values for lesions strongly correlated with K_i values obtained from full 2CM analysis for both tracers, whereas the multiparametric K_i values for normal organs, such as liver, spleen, and bone, were quantitative only for [¹⁸F]PSMA-1007. Overall, these results indicate that [¹⁸F]PSMA-1007 is better suited for quantitative multiparametric K_i imaging




Fig. 3 Examples of D-WB PET/CT scans performed in patients referred for primary staging of prostate cancer. SUV images are reconstructed using D-WB data from 60 to 70 min, whereas the parametric images of Ki and DV are reconstructed using D-WB data from 40 to 70 min. Above: the example of a D-WB PET/CT scan performed with $[^{68}\text{Ga}]\text{Ga-PSMA-11}$ displaying only primary disease (arrow). Below: one of the patients scanned with $[^{18}\text{F}]\text{PSMA-1007}$ showing primary disease in the prostate (thick arrow), dissemination to pelvic lymph nodes, as well as multiple small skeletal lesions in the ribs and left humerus (probably unspecific/benign) (thin arrows)

than $[^{68}\text{Ga}]\text{Ga-PSMA-11}$ as more organs exhibit irreversible kinetics. The observed difference can perhaps be attributed to the different binding potentials of the two tracers [36, 37]. Muscle tissue kinetics were best analysed by reversible 2CM for both tracers, probably due to the low muscular PSMA activity [5]. For $[^{18}\text{F}]\text{PSMA-1007}$, *Ki* values were quantitative both in healthy bone and bone lesions, which could allow for quantification

of disease progression. This may be of clinical interest since the threshold for pathology on static SUV images has been hard to establish due to the varying “normal” PSMA uptake in bones. Thus, we recommend using $[^{18}\text{F}]\text{PSMA-1007}$ for quantitative multiparametric *Ki* imaging in order to obtain images with unbiased quantifications of background organs and tissues, whereas both tracers can be used for lesion detection.




Fig. 4 Distribution of analysed VOIs showing a clear predominance of lesions favouring the tumour-to-background ratio in the parametric images. Main plot with distribution of all VOIs, insert with zoom on area 25×25 TBR. The triangle (Δ) symbol represents prostate lesions, circle (\circ) symbol represents lymph node lesions, square (\square) symbol represents bone lesions

The main advantage of PSMA D-WB multiparametric images over static SUV images is that the former allow for differentiation between free unbound tracer (background) and tracer bound to the PSMA receptors. K_i images are therefore characterized by improved target-to-background ratio, which in theory could improve lesion identification. However, even though tumour-to-background ratios were in general more favourable on our K_i images, we identified no additional pathologic lesions in this patient cohort. This result is similar to that of previous larger studies [11, 14] and attests to the known robustness of conventional SUV imaging.

^{18}F PSMA-1007 is often preferred by clinical departments due to its supposedly superior properties evaluating pathology in the pelvis, and the absence of reliance on an onsite gallium-68 generator. However, in our hands, both PSMA tracers identified primary prostatic disease with ease, regardless of whether images were static SUV or parametric K_i images. However, the improvement in regional TBR contrast associated with ^{18}F PSMA-1007 is likely to be more clinically relevant in relapse evaluation studies, of which we only had three in our cohort. Furthermore, it is recommended to administer furosemide shortly before or after administration of ^{68}Ga Ga-PSMA-11 [38], thus diminishing the high residual activity in the bladder [39]. Our protocol lacks such intervention, as it would reduce patient compliance with the prolonged scan time. Finally, this disadvantage

associated with ^{68}Ga Ga-PSMA-11 scanning can also be circumvented using D-WB imaging which provides better TBR (in this case PCa to bladder) of the *early* dynamic images [12, 15, 40]. Whether this potentially translates to improved detection of recurrent disease by D-WB ^{68}Ga Ga-PSMA-11 remains to be clarified in a larger study.

Both radiotracers readily identified lymph node metastases, although with higher K_i values in the ^{68}Ga Ga-PSMA-11 images. Likewise, skeletal lesion ^{68}Ga Ga-PSMA-11 activity was greater in static SUV images and calculated K_i values were higher in the parametric images. Coupled with the generally higher background signal in the bone observed in ^{18}F PSMA-1007 PET images, these findings seem to suggest that ^{68}Ga Ga-PSMA-11 PET should outperform ^{18}F PSMA-1007 PET in both lymph node and bone lesion detection. However, previous head-to-head studies based on static images have shown more bone lesions detected using static ^{18}F PSMA-1007 PET than ^{68}Ga Ga-PSMA-11. This is now a known disadvantage of ^{18}F PSMA-1007, as up to half of these additional bone ‘lesions’ have turned out to be benign [41, 42], and consequently, no difference in radiotracer sensitivity to detect malignant skeletal lesions have been reported [43, 44]. Although histological verification was not available in all lesions in the current study, it is evident to us that some of the delineated bone lesions with ^{18}F PSMA-1007, particularly those in the ribs and with low SUV values, likely also represent unspecific benign lesions [41, 42]. The presence of such unspecific bone lesions can contribute to the difference in distribution of SUV signal observed in Fig. 5, as the ^{68}Ga Ga-PSMA-11 cohort included a larger amount of likely bone metastases. The bone lesions were also visible on parametric PSMA PET using both radiotracers, which is unsurprising even though these lesions are probably visualized due to a non-PSMA-related uptake mechanism [45].

Consequently, parametric images cannot be used to differentiate these unspecific bone lesions from malignant disease, regardless of radiotracer used or scan protocol employed.

Whereas sensitivity to detect lesions was not improved by the parametric imaging, specificity appears to be slightly better. In our cohort of 20 patients, we observed two cases of ‘false-positive’ findings in soft-tissue lesions on the SUV images that showed no tracer uptake on the parametric reconstructions, as previously reported for ^{18}F FDG [25]. However, it is relevant to note that the presence of isolated soft-tissue or lymph node metastasis in the upper extremities is highly unlikely in prostate cancer.

Some limitations to the study must be acknowledged. First, the patient cohort is rather small, and for ethical




Fig. 5 Distribution of analysed volumes of interest **A** in healthy organs; **B** for malignant lesions in the prostate, lymph nodes and skeletal structures. Represented are SUV_{mean} (on the left) and Ki_{mean} (on the right) for both tracers. $[^{68}Ga]Ga$ -PSMA-11 in represented in blue, $[^{18}F]PSMA$ -1007 in red

reasons, patients were not subjected to repeat studies using the two different radiotracers. A direct comparison of findings in each study was therefore not possible. Studying the same patients with both tracers would have been optimal to minimize inter-individual variation in tumour biology, dissemination patterns and length of disease. Second, only a small fraction of patients in our cohort were scanned for disease relapse evaluation, which in theory should be the most promising referral indication, since putative lesions are located in the pelvic area with high background on $[^{68}Ga]$

Ga -PSMA-11 PET. However, suspected disease relapse only represents a fraction of PSMA PET referrals at our department. Third, we lack histological confirmation of our findings. However high correlation between imaging and histopathologic findings has been previously demonstrated for PSMA tracers [46, 47]. Finally, although all multiparametric images were based on 30-min D-WB PET data, the dynamic image acquisition protocols were not entirely identical. In a more elegant study setup, we would have preferred identical D-WB PET acquisition protocols.




Fig. 6 Correlation of SUV_{mean} and K_i_{mean} for lesions. On the left: [⁶⁸Ga]Ga-PSMA-11; on the right: [¹⁸F]PSMA-1007. Inserts containing the lower ranges of SUV_{mean} and K_i_{mean} can be seen on both plots

In conclusion, it is possible to perform D-WB PSMA PET scans that generate lesion and tissue K_i values in a clinical setting by using a multiparametric acquisition protocol on standard FOV PET scanners. Both [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007 can be used for lesion detection, with parametric PSMA K_i images showing superior lesion TBR. However, in our small cohort, K_i images did not uncover any additional lesions. For quantitative whole-body K_i imaging, [¹⁸F]PSMA-1007 is the preferred choice due to its predominantly irreversible kinetics in organs and lesions, leading to unbiased quantitative values.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13550-023-00981-8>.

Additional file 1. Table S1: VOI delineation methodology. **Figure S1:** Example of target and background delineation. **Figure S2:** Akaike information criterion (AIC) results comparison between the fit for an irreversible and reversible 2-compartment model for both tracers. **Figure S3A:** Kinetic analysis for the liver and spleen for both tracers. **Figure S3B:** Kinetic analysis for the healthy bone and muscle for both tracers. **Figure S3C:** Kinetic analysis for the lesions in the lymph nodes and in the bone for both tracers. **Figure S4:** Correlation between multiparametric K_i values and manual TAC-based K_i estimates using PMOD's PKIN module. **Figure S5:** Two examples of "false-positive" findings. Both [⁶⁸Ga]Ga-PSMA-11 scans. **Figure S6:** A case of HCC identified in the patient cohort, D-WB scan with [⁶⁸Ga]Ga-PSMA-11. **Figure S7:** Relations of prostate and bladder activity for both tracers. **Figure S8:** Distribution of analysed volumes of interest in benign ganglia with active PSMA uptake. **Figure S9:** Distribution of SUV_{max} values in the analysed volumes of interest in both healthy organs; and for malignant lesions in the prostate, lymph nodes and skeletal structures.

Author contributions

AHD, OLM, and LCG conceived the study. AHD processed data, analysed all images, delineated regions of interest, performed statistics and studied

semi-quantifications, and wrote the final version of the manuscript. MRJ recruited the [⁶⁸Ga]Ga-PSMA-11 cohort patients and analysed all images. AHD, MRJ, HDZ, OLM, and LCG joined in the discussions and editing the manuscript. All authors read and approved the final manuscript.

Funding

This project was partly funded by Siemens Healthineers. LCG and OLM are supported by an unrestricted grant from The Novo Nordisk Foundation (NNF19OC0055100). MRJ is financially supported by NEYE-Fonden and Fabrikant Einar Willumsens Mindelegat. The participating researchers are paid by their institutions and have no affiliation with the study's financial sponsors.

Availability of data and materials

Within the restrictions applied by the EU GDPR, all data are available from the authors upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the local ethics committee in Central Denmark Region (1-10-72-188-19). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from each patient before inclusion into the study.

Consent for publication

Consent for publication was obtained from each participant before inclusion into the study.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200 Aarhus N, Denmark. ²Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark. ³Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. ⁴Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Received: 11 November 2022 Accepted: 31 March 2023

Published online: 15 April 2023

References

- [1] S Hassanipour-Azgoni A Mohammadian-Hafshejani M Ghoncheh F Towhidi S Jamehshorani H Salehiniya 2016 Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide *Prostate Int.* <https://doi.org/10.1016/j.pnml.2016.07.001>
- [2] FH Schröder J Hugosson MJ Roobol TL Tammela S Ciatto V Nelen 2012 Prostate-cancer mortality at 11 years of follow-up *New Engl J Med* <https://doi.org/10.1056/NEJMoa1113135>
- [3] F Ceci DE Oprea-Lager L Emmett JA Adam J Bomanji J Czernin 2021 E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-021-05245-y>
- [4] A Farolfi L Calderoni F Mattana R Mei S Telo S Fanti 2021 Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer *J Nucl Med* <https://doi.org/10.2967/jnumed.120.257238>
- [5] Y Kinoshita K Kuratsukuri S Landas K Imaida PM Rovito CY Wang 2006 Expression of prostate-specific membrane antigen in normal and malignant human tissues *World J Surg.* <https://doi.org/10.1007/s00268-005-0544-5>
- [6] S Sheikhabaehi RA Werner LB Solnes KJ Pienta MG Pomper MA Gorin 2019 Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls *Semin Nucl Med.* <https://doi.org/10.1053/j.semnuclmed.2019.02.006>
- [7] HJ Wester M Schottelius 2019 PSMA-targeted radiopharmaceuticals for imaging and therapy *Semin Nucl Med.* <https://doi.org/10.1053/j.semnuclmed.2019.02.008>
- [8] F Haupt L Dijkstra I Alberts C Sachpekidis V Fech S Boxler 2020 68 Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-019-04548-5>
- [9] I Alberts C Sachpekidis E Gourni S Boxler T Gross G Thalmann 2020 Dynamic patterns of [68 Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-019-04545-8>
- [10] C Sachpekidis K Kopka M Eder BA Hadaschik MT Freitag L Pan 2016 68Ga-PSMA-11 dynamic PET/CT imaging in primary prostate cancer *Clin Nucl Med.* <https://doi.org/10.1097/RLU.0000000000001349>
- [11] C Sachpekidis M Eder K Kopka W Mier BA Hadaschik U Haberkorn 2016 (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-015-3302-4>
- [12] C Sachpekidis L Pan BA Hadaschik K Kopka U Haberkorn A Dimitrakopoulou-Strauss 2018 68 Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis *Am J Nucl Med Mol Imaging* 8 351
- [13] A Ringheim GC Campos Neto U Anazodo L Cui ML Cunha da T Vitor 2020 Kinetic modeling of 68 Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients *EJNMMI Res.* <https://doi.org/10.1186/s13550-020-0594-6>
- [14] C Sachpekidis A Afshar-Oromieh K Kopka DS Strauss L Pan U Haberkorn 2020 18 F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-019-04569-0>
- [15] DS Strauss C Sachpekidis K Kopka L Pan U Haberkorn A Dimitrakopoulou-Strauss 2021 Pharmacokinetic studies of [68 Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-021-05420-1>
- [16] J Wen Y Zhu L Li J Liu Y Chen R Chen 2021 Determination of optimal 68 Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-021-05659-8>
- [17] S Schmuck M Mamach F Wilke CA Klot von C Henkenberens JT Thackeray 2017 Multiple time-point 68Ga-PSMA I&T PET/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging *Clin Nucl Med.* <https://doi.org/10.1097/RLU.0000000000001589>
- [18] NA Karakatsanis MA Lodge AK Tahari Y Zhou RL Wahl A Rahmim 2013 Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application *Phys. Med Biol* 58 7391 418 <https://doi.org/10.1088/0031-9155/58/20/7391>
- [19] NA Karakatsanis MA Lodge Y Zhou RL Wahl A Rahmim 2013 Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation *Phys Med Biol.* 58 7419 45 <https://doi.org/10.1088/0031-9155/58/20/7419>
- [20] CS Patlak RG Blasberg JD Fenstermacher 1983 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data *J Cereb Blood Flow Metab.* 3 1 7 <https://doi.org/10.1038/jcbfm.1983.1>
- [21] CS Patlak RG Blasberg 1985 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations *J Cereb Blood Flow Metab* 5 584 90 <https://doi.org/10.1038/jcbfm.1985.87>
- [22] A Rahmim MA Lodge NA Karakatsanis VY Panin Y Zhou A McMillan 2019 Dynamic whole-body PET imaging: principles, potentials and applications *Eur J Nucl Med Mol Imaging.* 46 501 18 <https://doi.org/10.1007/s00259-018-4153-6>
- [23] A Dimitrakopoulou-Strauss L Pan C Sachpekidis 2022 Parametric imaging with dynamic PET for oncological applications: protocols, interpretation, current applications and limitations for clinical use *Semin Nucl Med* <https://doi.org/10.1053/j.semnuclmed.2021.10.002>
- [24] A Dimitrakopoulou-Strauss L Pan C Sachpekidis 2021 Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives *Eur J Nucl Med Mol Imaging.* 48 21 39 <https://doi.org/10.1007/s00259-020-04843-6>
- [25] AH Dias MF Pedersen H Danielsen OL Munk LC Gormsen 2021 Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body 18 F-FDG PET/CT scans *Eur J Nucl Med Mol Imaging.* <https://doi.org/10.1007/s00259-020-05007-2>
- [26] G Fahrni NA Karakatsanis G Domenicantonio Di V Garibotto H Zaidi 2019 Does whole-body Patlak (18)F-FDG PET imaging improve lesion detectability in clinical oncology? *Eur Radiol.* 29 4812 21 <https://doi.org/10.1007/s00330-018-5966-1>
- [27] AH Dias AK Hansen OL Munk LC Gormsen 2022 Normal values for 18 F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients *EJNMMI Res.* <https://doi.org/10.1186/s13550-022-00884-0>
- [28] Y Tao Z Peng A Krishnan XS Zhou 2011 Robust learning-based parsing and annotation of medical radiographs *IEEE Trans Med Imaging.* 30 338 50 <https://doi.org/10.1109/tmi.2010.2077740>
- [29] Dias AH, Pigg D, Smith AM, Shah V, Gormsen LC, Munk OL. Clinical validation of a population-based input function for dynamic whole-body 18F-FDG multiparametric PET imaging using a standard injector. In: 34th Annual Congress of the European Association of Nuclear Medicine: *Eur J Nucl Med Mol Imaging*; 2021. p. (Suppl 1) 198–9.
- [30] LM Mittlmeier M Brendel L Beyer NL Albert A Todica MJ Zacherl 2021 Feasibility of different tumor delineation approaches for 18 F-PSMA-1007 PET/CT imaging in prostate cancer patients *Front Oncol* <https://doi.org/10.3389/fonc.2021.663631>
- [31] AJ Reader J Verhaeghe 2014 4D image reconstruction for emission tomography *Phys Med Biol.* <https://doi.org/10.1088/0031-9155/59/22/R371>
- [32] S Yao T Feng Y Zhao R Wu R Wang S Wu 2021 Simplified protocol for whole-body Patlak parametric imaging with 18 F-FDG PET/CT: feasibility and error analysis *Med Phys* <https://doi.org/10.1002/mp.14187>
- [33] Z Chalampalakis S Stute M Filipović F Sureau C Comtat 2021 Use of dynamic reconstruction for parametric Patlak imaging in dynamic whole body PET *Phys Med Biol.* <https://doi.org/10.1088/1361-6560/ac2128>
- [34] J Logan JS Fowler ND Volkow AP Wolf SL Dewey DJ Schlyer 1990 Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects *J Cereb Blood Flow Metab* <https://doi.org/10.1038/jcbfm.1990.127>
- [35] H Akaike 1974 A new look at the statistical model identification *IEEE Trans Autom Control.* 19 716 23 <https://doi.org/10.1109/TAC.1974.1100705>
- [36] M Eder M Schäfer U Bauder-Wüst WE Hull C Wängler W Mier 2012 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging *Bioconjugate Chem* <https://doi.org/10.1021/bc200279b>
- [37] J Cardinale M Schäfer M Benešová U Bauder-Wüst K Leotta M Eder 2017 Preclinical evaluation of 18 F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging *J Nucl Med* <https://doi.org/10.2967/jnumed.116.181768>

- [38] WP Fendler M Eiber M Beheshti J Bomanji F Ceci S Cho 2017 68 Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 Eur J Nucl Med Mol Imaging. <https://doi.org/10.1007/s00259-017-3670-z>
- [39] T Derlin D Weiberg C Klot von HJ Wester C Henkenberens TL Ross 2016 68 Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging Eur Radiol. <https://doi.org/10.1007/s00330-016-4308-4>
- [40] C Uprimny AS Kroiss C Decristoforo J Fritz B Warwitz L Scarpa 2017 Early dynamic imaging in 68 Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions Eur J Nucl Med Mol Imaging. <https://doi.org/10.1007/s00259-016-3578-z>
- [41] EG Arnfield PA Thomas MJ Roberts AM Pelecanos SC Ramsay CY Lin 2021 Clinical insignificance of [18 F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation Eur J Nucl Med Mol Imaging. <https://doi.org/10.1007/s00259-021-05456-3>
- [42] H Grünig A Maurer Y Thali Z Kovacs K Strobel IA Burger 2021 Focal unspecific bone uptake on [18 F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging Eur J Nucl Med Mol Imaging. <https://doi.org/10.1007/s00259-021-05424-x>
- [43] S Hoberück S Löck A Borkowetz U Sommer R Winzer K Zöphel 2021 Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18 F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis EJNMMI Res <https://doi.org/10.1186/s13550-021-00845-z>
- [44] I Rauscher M Krönke M König A Gafta T Maurer T Horn 2020 Matched-pair comparison of 68 Ga-PSMA-11 PET/CT and 18 F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy J Nucl Med <https://doi.org/10.2967/jnumed.119.229187>
- [45] B Vollnberg I Alberts V Genitsch A Rominger A Afshar-Oromieh 2022 Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies Eur J Nucl Med Mol Imaging. <https://doi.org/10.1007/s00259-022-05745-5>
- [46] MS Hofman N Lawrentschuk RJ Francis C Tang I Vela P Thomas 2020 Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Lancet [https://doi.org/10.1016/S0140-6736\(20\)30314-7](https://doi.org/10.1016/S0140-6736(20)30314-7)
- [47] T Maurer JE Gschwend I Rauscher M Souvatzoglou B Haller G Weirich 2016 Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer J Urol <https://doi.org/10.1016/j.juro.2015.12.025>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)
